

# Jason A Somarelli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7904271/publications.pdf>

Version: 2024-02-01

73  
papers

2,458  
citations

331670

21  
h-index

254184

43  
g-index

90  
all docs

90  
docs citations

90  
times ranked

3830  
citing authors

#	ARTICLE	IF	CITATIONS
1	Identifying Modifiable and Non-modifiable Risk Factors of Readmission and Short-Term Mortality in Chondrosarcoma: A National Cancer Database Study. <i>Annals of Surgical Oncology</i> , 2022, 29, 1392-1408.	1.5	2
2	ASO Author Reflections: Identifying Modifiable and Non-Modifiable Risk Factors of Readmission and Short-Term Mortality in Chondrosarcoma. <i>Annals of Surgical Oncology</i> , 2022, 29, 1409-1410.	1.5	1
3	Extent of tumor fibrosis/hyalinization and infarction following neoadjuvant radiation therapy is associated with improved survival in patients with soft-tissue sarcoma. <i>Cancer Medicine</i> , 2022, 11, 194-206.	2.8	5
4	A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 762-769.	3.9	13
5	Post-Austronesian migrational wave of West Polynesians to Micronesia. <i>Gene</i> , 2022, 823, 146357.	2.2	1
6	Characterization of a castrate-resistant prostate cancer xenograft derived from a patient of West African ancestry. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 513-523.	3.9	2
7	Questions to guide cancer evolution as a framework for furthering progress in cancer research and sustainable patient outcomes. , 2022, 39, .		7
8	Exploring the Diversity of the Marine Environment for New Anti-cancer Compounds. <i>Frontiers in Marine Science</i> , 2021, 7, .	2.5	22
9	Analysis of immune subtypes across the epithelial-mesenchymal plasticity spectrum. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 3842-3851.	4.1	18
10	Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer. <i>Biomarker Research</i> , 2021, 9, 14.	6.8	24
11	The Hallmarks of Cancer as Ecologically Driven Phenotypes. <i>Frontiers in Ecology and Evolution</i> , 2021, 9, .	2.2	24
12	Identifying Modifiable and Non-modifiable Risk Factors of Readmission and Short-Term Mortality in Osteosarcoma: A National Cancer Database Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 7961-7972.	1.5	5
13	ASO Visual Abstract: Identifying Modifiable and Non-Modifiable Risk Factors of Readmission and Short-Term Mortality in Osteosarcoma—A National Cancer Database Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 449-450.	1.5	1
14	The somatic molecular evolution of cancer: Mutation, selection, and epistasis. <i>Progress in Biophysics and Molecular Biology</i> , 2021, 165, 56-65.	2.9	11
15	A Zebrafish Model of Metastatic Colonization Pinpoints Cellular Mechanisms of Circulating Tumor Cell Extravasation. <i>Frontiers in Oncology</i> , 2021, 11, 641187.	2.8	6
16	Treatment of Chondroblastoma with Denosumab. <i>JBJS Case Connector</i> , 2021, 11, .	0.3	3
17	An integrated comparative physiology and molecular approach pinpoints mediators of breath-hold capacity in dolphins. <i>Evolution, Medicine and Public Health</i> , 2021, 9, 420-430.	2.5	5
18	KLF4 Induces Mesenchymal-Epithelial Transition (MET) by Suppressing Multiple EMT-Inducing Transcription Factors. <i>Cancers</i> , 2021, 13, 5135.	3.7	21

#	ARTICLE	IF	CITATIONS
19	ASO Visual Abstract: Identifying Modifiable and Non-Modifiable Risk Factors of Readmission and Short-Term Mortality in Chondrosarcoma: A National Cancer Database Study. <i>Annals of Surgical Oncology</i> , 2021, , 1.	1.5	1
20	Abstract P204: Targeting the p300/CBP epigenetic pathway to overcome hormone therapy resistance in advanced prostate cancer. , 2021, , .		0
21	Immune dysregulation and osteosarcoma: <i>Staphylococcus aureus</i> downregulates TGF $\beta$ <sup>2</sup> and heightens the inflammatory signature in human and canine macrophages suppressed by osteosarcoma. <i>Veterinary and Comparative Oncology</i> , 2020, 18, 64-75.	1.8	14
22	Molecular Biology and Evolution of Cancer: From Discovery to Action. <i>Molecular Biology and Evolution</i> , 2020, 37, 320-326.	8.9	43
23	Improving Cancer Drug Discovery by Studying Cancer across the Tree of Life. <i>Molecular Biology and Evolution</i> , 2020, 37, 11-17.	8.9	20
24	Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 225-239.	2.8	18
25	Plastic pollution solutions: emerging technologies to prevent and collect marine plastic pollution. <i>Environment International</i> , 2020, 144, 106067.	10.0	200
26	Phenotypic plasticity and lineage switching in prostate cancer. , 2020, , 591-615.		3
27	A Comparative Oncology Drug Discovery Pipeline to Identify and Validate New Treatments for Osteosarcoma. <i>Cancers</i> , 2020, 12, 3335.	3.7	11
28	Limb salvage versus amputation in patients with osteosarcoma of the extremities: an update in the modern era using the National Cancer Database. <i>BMC Cancer</i> , 2020, 20, 995.	2.6	43
29	A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2516-2527.	4.1	17
30	Preclinical Testing of a Novel Niclosamide Stearate Prodrug Therapeutic (NSPT) Shows Efficacy Against Osteosarcoma. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1448-1461.	4.1	17
31	From the Clinic to the Bench and Back Again in One Dog Year: How a Cross-Species Pipeline to Identify New Treatments for Sarcoma Illuminates the Path Forward in Precision Medicine. <i>Frontiers in Oncology</i> , 2020, 10, 117.	2.8	18
32	Development of a precision medicine pipeline to identify personalized treatments for colorectal cancer. <i>BMC Cancer</i> , 2020, 20, 592.	2.6	14
33	Baby Genomics: Tracing the Evolutionary Changes That Gave Rise to Placentation. <i>Genome Biology and Evolution</i> , 2020, 12, 35-47.	2.5	11
34	A precision medicine drug discovery pipeline to identify dual CDK2/9 inhibition as a novel treatment for colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e16056-e16056.	1.6	0
35	Abstract A114: Characterization of a metastatic prostate cancer xenograft derived from a patient of African ancestry. , 2020, , .		0
36	Manganese Porphyrin and Radiotherapy Improves Local Tumor Response and Overall Survival in Orthotopic Murine Mammary Carcinoma Models. <i>Radiation Research</i> , 2020, 195, 128-139.	1.5	2

#	ARTICLE	IF	CITATIONS
37	Association of circulating tumor cell chromosomal instability with worse outcomes in men with mCRPC treated with abiraterone or enzalutamide.. Journal of Clinical Oncology, 2020, 38, 183-183.	1.6	1
38	Bioengineering a Future Free of Marine Plastic Waste. Frontiers in Marine Science, 2019, 6, .	2.5	33
39	Molecular determinants for enzalutamide-induced transcription in prostate cancer. Nucleic Acids Research, 2019, 47, 10104-10114.	14.5	27
40	The Marquesans at the fringes of the Austronesian expansion. European Journal of Human Genetics, 2019, 27, 801-810.	2.8	6
41	Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer. PLoS ONE, 2019, 14, e0216934.	2.5	14
42	E-Cadherin Represses Anchorage-Independent Growth in Sarcomas through Both Signaling and Mechanical Mechanisms. Molecular Cancer Research, 2019, 17, 1391-1402.	3.4	35
43	Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. Journal of Clinical Oncology, 2019, 37, 1120-1129.	1.6	267
44	An Integrative Systems Biology and Experimental Approach Identifies Convergence of Epithelial Plasticity, Metabolism, and Autophagy to Promote Chemoresistance. Journal of Clinical Medicine, 2019, 8, 205.	2.4	17
45	Soft Tissue Sarcoma of the Extremities: What Is the Value of Treating at High-volume Centers?. Clinical Orthopaedics and Related Research, 2019, 477, 718-727.	1.5	46
46	Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas. , 2019, 194, 161-184.		244
47	The PROPHECY trial: Multicenter prospective trial of circulating tumor cell (CTC) AR-V7 detection in men with mCRPC receiving abiraterone (A) or enzalutamide (E).. Journal of Clinical Oncology, 2018, 36, 5004-5004.	1.6	8
48	A precision medicine strategy to identify the FGFR pathway as a novel target in colorectal cancer liver metastasis.. Journal of Clinical Oncology, 2018, 36, 660-660.	1.6	0
49	Genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells from men with metastatic castration resistant prostate cancer (mCRPC) treated with radium-223.. Journal of Clinical Oncology, 2018, 36, 160-160.	1.6	1
50	Genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells from men with metastatic castration resistant prostate cancer (mCRPC) treated with radium-223.. Journal of Clinical Oncology, 2018, 36, 5029-5029.	1.6	0
51	Abstract B038: Convergent hormone therapy resistance mediated by stress/dormancy-like pathways in prostate cancer. , 2018, , .		0
52	<scp>EMT</scp> and <scp>MET</scp>: necessary or permissive for metastasis?. Molecular Oncology, 2017, 11, 755-769.	4.6	319
53	Epithelial/mesenchymal plasticity: how have quantitative mathematical models helped improve our understanding?. Molecular Oncology, 2017, 11, 739-754.	4.6	64
54	Survival Outcomes in Cancer Patients Predicted by a Partial EMT Gene Expression Scoring Metric. Cancer Research, 2017, 77, 6415-6428.	0.9	206

#	ARTICLE	IF	CITATIONS
55	Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells. <i>Journal of Visualized Experiments</i> , 2017, , .	0.3	4
56	PhyloOncology: Understanding cancer through phylogenetic analysis. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1867, 101-108.	7.4	22
57	Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 1346-1357.	7.0	58
58	Mesenchymal-Epithelial Transition in Sarcomas Is Controlled by the Combinatorial Expression of MicroRNA 200s and GRHL2. <i>Molecular and Cellular Biology</i> , 2016, 36, 2503-2513.	2.3	88
59	Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer. <i>Oncotarget</i> , 2016, 7, 50507-50521.	1.8	44
60	Carcinosarcomas: tumors in transition?. <i>Histology and Histopathology</i> , 2015, 30, 673-87.	0.7	21
61	The role of epithelial plasticity in prostate cancer dissemination and treatment resistance. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 441-468.	5.9	59
62	Cellular Migration and Invasion Uncoupled: Increased Migration Is Not an Inexorable Consequence of Epithelial-to-Mesenchymal Transition. <i>Molecular and Cellular Biology</i> , 2014, 34, 3486-3499.	2.3	80
63	U1 small nuclear RNA variants differentially form ribonucleoprotein particles in vitro. <i>Gene</i> , 2014, 540, 11-15.	2.2	7
64	Abstract SS02-02: A long walk from FGFR2 alternative splicing to cancer progression. , 2014, , .		0
65	Fluorescence-based alternative splicing reporters for the study of epithelial plasticity in vivo. <i>Rna</i> , 2013, 19, 116-127.	3.5	25
66	Genome-based identification of spliceosomal proteins in the silk moth <i>Bombyx mori</i> . <i>Archives of Insect Biochemistry and Physiology</i> , 2010, 75, 231-263.	1.5	1
67	A three-dimensional model of the U1 small nuclear ribonucleoprotein particle. <i>Entomological Research</i> , 2010, 40, 104-112.	1.1	2
68	Alternative splicing in multiple sclerosis and other autoimmune diseases. <i>RNA Biology</i> , 2010, 7, 462-473.	3.1	66
69	U2 snRNA variants are differentially incorporated into spliceosomes. <i>Entomological Research</i> , 2009, 39, 135-145.	1.1	3
70	To what extent did Neanderthals and modern humans interact?. <i>Biological Reviews</i> , 2009, 84, 245-257.	10.4	20
71	Small nuclear RNA variants of three <i>Bombyx mori</i> strains. <i>Entomological Research</i> , 2008, 38, 61-68.	1.1	3
72	Spliceosomal immunophilins. <i>FEBS Letters</i> , 2008, 582, 2345-2351.	2.8	20

#	ARTICLE	IF	CITATIONS
73	Evolution of the 12 kDa FK506-binding protein gene. <i>Biology of the Cell</i> , 2007, 99, 311-321.	2.0	31